ÂÜÀòÂÒÂ×

Michael Grimm is a seasoned professional in the field of medicine with extensive experience in clinical development and research. Currently serving as the Head of Metabolic Diseases at Regor Therapeutics Group, Michael has previously held significant roles including Senior Medical Advisor and Chief Medical Officer at ProSciento, Inc., as well as Vice President of Cardiovascular Clinical Development at a Stealth Biotech Startup. Additionally, Michael has worked as Executive Director in both Clinical Development at AnaptysBio and Clinical Research at MyoKardia. Michael holds a Doctorate in Medicine (PhD) in Pharmacology and a Doctor of Medicine (MD), both from Universität Hamburg in Germany.